<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="659">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152576</url>
  </required_header>
  <id_info>
    <org_study_id>M21-606</org_study_id>
    <nct_id>NCT05152576</nct_id>
  </id_info>
  <brief_title>A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA X for Forehead Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Facial lines that develop from repeated facial expression, such as forehead lines (FHL), are&#xD;
      typically treated by selectively weakening specific muscles with small quantities of&#xD;
      botulinum toxin. OnabotulinumtoxinA X is being investigated as another form of treatment to&#xD;
      treat FHL by inhibiting the release of the neurotransmitter that causes the overactivity of&#xD;
      the muscles responsible for the severity of these facial lines. The purpose of this study is&#xD;
      to evaluate the safety and change in condition of 3 doses of OnabotulinumtoxinA X for the&#xD;
      treatment of moderate to severe forehead lines.&#xD;
&#xD;
      Study doctors will determine if a subject is eligible for the study. If so, the subject will&#xD;
      be randomized into 1 of the 4 groups, called treatment arms. There is a 1 in 4 chance that a&#xD;
      participant will be assigned to placebo. Around 120 adult participants with FHL will be&#xD;
      enrolled in the study in approximately 10 sites in the United States.&#xD;
&#xD;
      Participants will receive either intramuscular injections of onabotulinumtoxinA X or placebo.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular monthly visits during the study at the&#xD;
      study site.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a casual relationship with this treatment. The investigator assesses the relationship of each event to the use of the study. A serious adverse event (SAE) is an event that results in death, is life threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event, that based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Potentially Clinically Significant Vital Sign Parameters</measure>
    <time_frame>Day 1 to Day 180</time_frame>
    <description>Percentage of participants with potentially clinically significant vital sign measurements like systolic and diastolic blood pressure will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Achievement of â‰¥ 1-grade improvement from baseline on the investigator-rated clinician forehead lines Scale at maximum contraction.</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>The Clinician Forehead Lines Scale is a four point scale used to assess the severity of forehead lines at maximum contraction ranging from 0 - None to 3 - Severe</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Forehead Lines</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be injected into the forehead on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA X Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA X will be injected into the forehead on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA X Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA X will be injected into the forehead on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA X Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA X will be injected into the forehead on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OnabotulinumtoxinA X</intervention_name>
    <description>Intramuscular Injection</description>
    <arm_group_label>OnabotulinumtoxinA X Dose A</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA X Dose B</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA X Dose C</arm_group_label>
    <other_name>OnabotA X</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular Injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has sufficient visual acuity without the use of eyeglasses (contact lens&#xD;
             use is acceptable) to accurately assess their facial lines&#xD;
&#xD;
          -  Participant has moderate or severe Forehead Lines (FHL) at maximum eyebrow elevation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of known immunization to any botulinum toxin serotype.&#xD;
&#xD;
          -  History of known hypersensitivity to any botulinum toxin serotype, or any other&#xD;
             constituents of the study drug or its excipients, and/or other products in the same&#xD;
             class.&#xD;
&#xD;
          -  Presence or history of any medical condition that may place the participant at&#xD;
             increased risk following exposure to OnabotulinumtoxinA X or interfere with the study&#xD;
             evaluation, including:&#xD;
&#xD;
        Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any&#xD;
        other significant disease that might interfere with neuromuscular function.&#xD;
&#xD;
          -  History of Facial nerve palsy.&#xD;
&#xD;
          -  Infection or dermatological condition at the site of study drug injection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Steve Yoelin MD Medical Assoc. Inc /ID# 239771</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663-3311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Eye Research Foundation /ID# 241512</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663-3637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Center for Dermatology Cosmetics &amp; Laser Surgery /ID# 239776</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549-3028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Search of Rochester Inc. /ID# 239773</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Service /ID# 239779</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wilmington Dermatology Center /ID# 239778</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dallas Plastic Surgery Institute /ID# 239777</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research /ID# 239783</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Forehead Lines</keyword>
  <keyword>OnabotulinumtoxinA X</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

